The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued positive opinions for Celltrion's (KRX:068270) biosimilars Eydenzelt (aflibercept), Stoboclo and Osenvelt (denosumab), and Avtozma (tocilizumab), Celltrion said Monday.

Eydenzelt, comparable to Eylea, targets retinal disorders such as wet AMD and diabetic macular edema. Stoboclo and Osenvelt are at par with Prolia and Xgeva for osteoporosis and cancer-related conditions. Avtozma is comparable to RoActemra for rheumatoid arthritis and other inflammatory diseases, the press release said.

The products require European Commission approval for marketing in the European Union.

Shares of Celltrion rose more than 1% in recent trade on Monday.